** Noxopharm NOX.AX soars 12.9% to A$0.096, snapping three sessions of declines
** Stock set for biggest intraday pct gain since Nov. 15, 2024
** Biotech co says its lupus medication has passed a set of pre-clinical safety tests, a requisite for drug development prior to Phase 1 clinical trial
** Around 326,347 shares traded, 2.3x the 30-day avg
** NOX gains 3.2% YTD
(Reporting by Jasmeen Ara Shaikh in Bengaluru)
((Jasmeenaraislam.shaikh@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。